Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $19.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target upped by equities research analysts at TD Cowen from $18.00 to $19.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen‘s target price points to a potential upside of 11.10% from the stock’s previous close.

RARE has been the subject of a number of other research reports. Bank of America cut Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating in a report on Thursday, September 3rd. Canaccord Genuity Group boosted their target price on shares of Ultragenyx Pharmaceutical from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. Morgan Stanley raised their price target on shares of Ultragenyx Pharmaceutical from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Wednesday. JPMorgan Chase & Co. downgraded shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $80.00 to $36.00 in a research note on Thursday, September 3rd. Finally, Barclays boosted their price objective on shares of Ultragenyx Pharmaceutical from $32.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $33.70.

Ultragenyx Pharmaceutical Trading Up 2.8%

Shares of RARE traded up $0.47 during midday trading on Wednesday, reaching $17.10. 4,231,209 shares of the company were exchanged, compared to its average volume of 2,856,926. The stock has a 50-day moving average price of $16.64 and a 200-day moving average price of $22.81. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -2.93 and a beta of 0.37. Ultragenyx Pharmaceutical has a 1-year low of $12.73 and a 1-year high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The firm had revenue of $173.00 million during the quarter, compared to analyst estimates of $182.49 million. The business’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the prior year, the business posted ($1.81) EPS. Equities research analysts anticipate that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current year.

Insider Activity

In related news, CFO Howard Horn sold 7,066 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the sale, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,510 shares of company stock valued at $127,561 in the last three months. 5.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Ultragenyx Pharmaceutical in the second quarter valued at about $355,746,000. Bank of America Corp DE bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $38,347,000. Jefferies Financial Group Inc. bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $31,040,000. Eagle Health Investments LP bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $29,521,000. Finally, Candriam S.C.A. grew its position in shares of Ultragenyx Pharmaceutical by 37.1% in the 1st quarter. Candriam S.C.A. now owns 1,096,182 shares of the biopharmaceutical company’s stock worth $22,965,000 after acquiring an additional 296,798 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability outlook. It expects substantial cost reductions, including at least a 50% decrease in 2027 R&D expenses versus 2025. The company also reported FDA approvals for GENGLYCOS and FAYUVI and agreements to sell two priority review vouchers for a combined $413 million. Ultragenyx Q3 results and outlook
• Positive Sentiment: Although the quarterly loss was wider than expected, it narrowed to $1.16 per share from $1.81 a year earlier, while revenue grew 8.2% year over year. Q3 earnings report
• Neutral Sentiment: Analyst views were mixed. Morgan Stanley raised its target to $22 and Wells Fargo to $19, both retaining equal-weight ratings; Wedbush cut its target to $22 but stayed neutral. Morgan Stanley ratings Wells Fargo ratings Wedbush ratings
• Negative Sentiment: Q3 revenue of $173 million fell short of the $182.49 million consensus, and the $1.16-per-share loss was slightly worse than expected. Goldman Sachs lowered its target from $19 to $17 and kept a neutral rating. Goldman Sachs ratings
• Negative Sentiment: A Seeking Alpha analysis argued that the profitability plan relies heavily on R&D cuts, while revenue remains concentrated in CRYSVITA and pipeline setbacks have narrowed the company’s growth prospects. Ultragenyx analysis

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.